GSK Shares Dive as Weak Vaccine Sales and Costs Spook Investors 2026

GSK shares took a sharp dive on Wednesday after the UK drugmaker reported weaker vaccine sales and mounting restructuring costs, rattling investors despite better-than-expected overall financial results. The stock fell as much as 7% before paring back to a 5.5% drop, making it the biggest faller on the FTSE 100 index of blue-chip businesses.

The pharmaceutical giant reported a 19% decline in pre-tax profit to £1.9bn for the July to September quarter, alongside £318m of restructuring charges—with more expected to come. The market's negative reaction underscores growing concerns about the company's growth trajectory under new leadership.

What Drove GSK Shares Down?

At the heart of the sell-off was a 2% dip in vaccine sales to £2.6bn. The decline was driven by sharp falls for two key products: the shingles shot Shingrix, down 5%, and the RSV vaccine Arexvy, down 24%. Those drops overshadowed a 12% rise in meningitis vaccine sales.

Investors were also spooked by the £318m restructuring charge and the prospect of further costs as CEO Luke Miels—who took over from Emma Walmsley in January—pushes ahead with a major cost-saving programme announced in July. That programme aims to speed up drug development, but the upfront expenses are weighing on sentiment.

Meanwhile, turnover rose 5% at constant currency rates to £8.9bn, thanks to strong sales of HIV, cancer and lupus medications. Yet the market chose to focus on the negatives, highlighting how sensitive GSK's valuation has become to vaccine performance and cost execution.

Why Vaccine Sales Matter So Much

Vaccines are a cornerstone of GSK's business, and the recent weakness in Shingrix and Arexvy is a red flag. Shingrix has been a growth engine for years, but a 5% decline suggests slowing demand or increased competition. Arexvy, a newer entrant in the RSV market, saw a 24% plunge—a worrying sign given the vaccine's potential.

These declines come as GSK faces a looming patent cliff for its blockbuster HIV drug dolutegravir, which loses patent protection towards the end of the decade. That will allow generic competitors to enter the market, potentially eroding a significant revenue stream. The company has set a goal of growing its vaccine and specialty medicine portfolios to offset this, but the latest quarter shows that path may be bumpy.

Leadership and Strategy Under Scrutiny

Luke Miels, who took the helm in January, has moved quickly to reshape GSK. He has announced a number of acquisitions, including a £7.9bn deal for a US cancer specialist, and launched a major cost-saving programme in July. These moves are designed to accelerate drug development and strengthen the pipeline, but they come with hefty restructuring charges.

Investors are clearly questioning whether the strategy will pay off quickly enough. The 5.5% share price drop suggests they want to see tangible results before buying into the new CEO's vision. With more restructuring charges expected, the pressure is on Miels to deliver.

What This Means for the FTSE 100 and UK Business

GSK is Britain's second-biggest pharmaceutical company, so its share price movements carry weight on the FTSE 100. The stock's decline on Wednesday was a drag on the index, and it highlights the challenges facing large UK corporates in a tough economic environment.

However, it's worth noting that GSK's underlying revenue growth remains positive, and its HIV and cancer franchises are performing well. The market's reaction may be an overcorrection, but it also signals that investors are demanding more clarity on the company's growth strategy and cost controls.

Key Takeaways for Investors

• GSK shares fell 5.5% despite better-than-expected results, as vaccine sales weakened.
• Pre-tax profit dropped 19% to £1.9bn, with £318m in restructuring charges and more to come.
• Shingrix and Arexvy vaccine sales declined, offsetting growth in HIV and cancer drugs.
• The looming patent cliff for dolutegravir adds to long-term uncertainty.
• New CEO Luke Miels faces pressure to deliver on acquisitions and cost savings.

Comparing GSK's Q3 Performance

What to Watch Next

Investors will be looking for signs that GSK's vaccine sales stabilize and that the restructuring programme begins to yield savings. The company's ability to navigate the dolutegravir patent cliff will also be critical. Any further acquisitions or strategic shifts under Miels will be closely scrutinized. The background to this story is set out in GSK Job Cuts: £1.9bn Cost-Cutting Plan and R&D Shift. A related thread runs through Rolls-Royce Outlook Improves: Is It the Next FTSE Leader?. Earlier coverage in Private Equity Targets London's FTSE 100: DCC Energy Deal shows how the argument developed.

More broadly, GSK's performance is a bellwether for the UK pharmaceutical sector. Its struggles could have implications for other UK drugmakers and for the government's efforts to promote life sciences investment. The company's next earnings report will be a key test of whether the current pessimism is justified. A closer look at the same subject appears in FTSE 100 Best Month Since Iran Attacks: Market Update. Anyone following the wider picture can start with FTSE 100 on Track for Best Month Since Iran Attacks. The same theme surfaces in DCC Energy £5.75bn Takeover: FTSE 100 Exodus Continues, which takes a different angle.

As GSK navigates these challenges, the market will be watching closely. For now, the share price reaction shows that investors are not yet convinced that the worst is over. Context on how this played out before sits in Rolls-Royce Outlook Improves: CEO Targets Top FTSE Spot. A companion piece, France Debt Sell-Off Deepens as Violent Protests Spook Investors, approaches the same subject from another angle.